News
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
Amgen (AMGN) ended the recent trading session at $272.44, demonstrating a -5.84% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.96%. Elsewhere, the Dow ...
Shares of American Express and Amgen are retreating Monday afternoon, dragging the Dow Jones Industrial Average into negative territory.
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...
Amgen Inc. (NASDAQ:AMGN) is one of the best next generation dividend aristocrat stocks. The company has built a solid track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback